Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 8/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 6/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23451975 | 0.80 | METAP2 (0.63) | NOTUMMETAP2 | |
| SCHEMBL27578676 | 0.75 | ERN1 (0.50) | NOTUMDYRK1ARIPK1 | |
| SCHEMBL21792334 | 0.75 | NOTUM (0.62) | NOTUMGSK3BMETAP2AXLMERTK | |
| SCHEMBL22471887 | 0.74 | DYRK1A (0.61) | NOTUMGSK3BDYRK1A | |
| SCHEMBL1395948 | 0.74 | GSK3B (0.55) | NOTUMGSK3BDYRK1A | |
| SCHEMBL13435542 | 0.72 | NPC1 (0.62) | GSK3BDYRK1A | |
| SCHEMBL3490039 | 0.71 | GSK3B (0.66) | GSK3BDYRK1A | |
| SCHEMBL459693 | 0.71 | CTNNB1 (0.49) | NOTUMDYRK1ARIPK1 | |
| SCHEMBL29674920 | 0.71 | CTNNB1 (0.49) | NOTUMDYRK1ARIPK1 | |
| SCHEMBL27578678 | 0.71 | CTNNB1 (0.47) | NOTUMDYRK1AAXLMERTKRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885GSK3B 877/4885DYRK1A 4811/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885GSK3B 1024/4885DYRK1A 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.